Literature DB >> 30622101

Xia-Gibbs syndrome in adulthood: a case report with insight into the natural history of the condition.

David R Murdock1,2, Yunyun Jiang1,2, Michael Wangler2,3, Michael M Khayat1,2, Aniko Sabo1,2, Jane Juusola4, Kirsty McWalter4, Krista Sondergaard Schatz5, Meral Gunay-Aygun5, Richard A Gibbs1,2.   

Abstract

A 55-yr-old male with severe intellectual disability, behavioral problems, kyphoscoliosis, and dysmorphic features was referred for a genetic evaluation. Chromosomal microarray, RASopathy gene panel, mitochondrial sequencing, and fragile X testing were all negative. Subsequent whole-exome sequencing revealed a heterozygous, truncating variant in the AHDC1 gene, consistent with a diagnosis of Xia-Gibbs syndrome (XGS). Review of his clinical history showed many classic dysmorphic and clinical features of XGS, but no major health issues in adulthood other than intellectual disability. This individual is the oldest published XGS case to date, demonstrates the wide phenotypic spectrum of the disorder, and provides information on the condition's natural history. As more adults undergo genomic studies, we will continue to learn about the adult phenotypes of genetic conditions typically diagnosed in the pediatric setting.
© 2019 Murdock et al.; Published by Cold Spring Harbor Laboratory Press.

Entities:  

Keywords:  intellectual disability, severe; severe global developmental delay

Mesh:

Year:  2019        PMID: 30622101      PMCID: PMC6549549          DOI: 10.1101/mcs.a003608

Source DB:  PubMed          Journal:  Cold Spring Harb Mol Case Stud        ISSN: 2373-2873


INTRODUCTION

De novo truncating variants in the AT-hook DNA-binding motif-containing 1 (AHDC1) gene cause autosomal dominant Xia–Gibbs syndrome (XGS: MIM 615829) (Xia et al. 2014). XGS is a multisystemic disorder characterized by significant intellectual disability. Affected individuals may also have hypotonia, dysmorphic features, seizures, and brain anomalies among other findings (Yang et al. 2015). Approximately 100 patients worldwide have been identified with XGS, nearly all of them in the pediatric age range and the oldest being 29 yr of age (García-Acero and Acosta 2017; Popp et al. 2017; Jiang et al. 2018; Ritter et al. 2018). To date, genomic scale sequencing has been widely adopted in the pediatric setting, where it has demonstrated a diagnostic rate of ∼25% (Yang et al. 2014). Despite examples of its benefit in older patients, it remains underutilized as a diagnostic tool in adults (Posey et al. 2016). Here we describe the use of whole-exome sequencing (WES) to diagnose an adult male with intellectual disability and further define the natural history of XGS.

RESULTS

Clinical Presentation and Family History

The major clinical features of this individual are listed in Table 1. Prenatal and early-childhood information is unavailable for the individual, except that he failed to meet developmental milestones for walking and speech. His first words occurred around 2 yr of age and he did not have the ability to speak in short sentences until after age 5 yr. His family describes his language issues as that of a person for whom “English is a second language, but they don't have a first language.” Other than a hernia operation at 2 mo of age, there were no severe childhood illnesses or surgeries until the age of 13 yr when he had his first grand mal seizure. He was treated with antiseizure medication (phenobarbital, ethotoin) until the age of 40 yr and has had no recurrence since stopping treatment. Other neurological symptoms include occasional severe frontal lobe headaches and hand tremors. He has an ataxic gait with poor balance. He is able to walk independently on flat ground but requires assistance if the ground is uneven. Brain magnetic resonance imaging (MRI) at age 52 yr was unremarkable except for generalized brain atrophy. Hearing and ophthalmologic exams have been normal.
Table 1.

Clinical features of this individual compared to previously described Xia–Gibbs syndrome (XGS) cases

XGS featuresPresent in this case
Common
 Developmental delayNoted at 6 mo of age
 Speech delayFirst words at age 2 yr, short sentences at 5 yr
 Intellectual disabilitySevere (IQ 30–40)
 Motor abnormalitiesAtaxic gait, poor balance
 Dysmorphic featuresMacrocephaly, prominent forehead, large ears
 Growth deficienciesShort stature
 Abnormal brain imagingMild atrophy
 Hypotonia-
 Airway obstruction-
Rare
 Spine anomaliesKyphoscoliosis
 Seizure historyYes, but none in last 15 yr (off medication)
 Behavioral issuesImpulse control, aggression, anxiety
 Connective tissue abnormalitySoft, loose skin
 Vision/hearing impairment-
 Craniosynostosis-
 Joint laxity-
Notable unique features
 NeoplasmsThyroid mass, nerve sheath tumor, melanoma
 HypertensionWell controlled with medication

Common and rare features of XGS were seen in >50% and < 50% of reported cases, respectively.

Clinical features of this individual compared to previously described Xia–Gibbs syndrome (XGS) cases Common and rare features of XGS were seen in >50% and < 50% of reported cases, respectively. The individual was diagnosed with kyphoscoliosis around age 10 yr (Fig. 1). Bracing was unsuccessful and corrective surgery was discussed but not pursued. Despite imaging showing 56° right thoracic scoliosis, he continues to be managed conservatively by his orthopedic surgeon with no related complications or pain. In his late 40s, he underwent resection of a nasal anterior skull base peripheral sheath tumor (detected incidentally by brain MRI) with pathology favoring a benign Schwannoma. A benign growth was removed from his thyroid at age 35 yr and he had melanoma in situ ×2 on his back. A baseline colonoscopy at age 52 yr was normal. Other notable chronic medical issues included severe bruxism, chronic constipation, and hypertension.
Figure 1.

Photo of patient's back demonstrating the significant right thoracic kyphoscoliosis measuring 56°. Loose skin is also evident.

Photo of patient's back demonstrating the significant right thoracic kyphoscoliosis measuring 56°. Loose skin is also evident. His neuropsychological history was significant for problems with impulse control, self-injurious, and aggressive behavior beginning in childhood. Such episodes are typically triggered by frustration, pain, fatigue, or unfamiliar stressful situations. He was once committed to a psychiatric hospital for extreme anxiety and violent behavior. He has had some success in reducing these episodes of anxiety with benzodiazepines. Cognitive testing as a child revealed a full-scale IQ between 30 and 40. He has been consistently talkative and social, and his expressive language is more advanced compared to other cognitive measures. He has lived with family members or in group homes his entire life and has not been formally schooled. He understands speech but is unable to read or write. Sleep disturbances have been lifelong. Beginning in his mid 40s, he has exhibited slowly progressive cognitive decline. He can follow simple commands but usually cannot follow complex (two-step or more) commands. He is able to answer binary but not open-ended questions. His speech has slowed but his overall ability and the number of words is stable. Many daily activities require assistance, including using the toilet and showering, but he is able to feed and dress himself. Urinary and fecal incontinence began in his early 50s and he now wears a diaper at all times. The individual is the third child of his parents who had an additional pregnancy that ended in a spontaneous miscarriage. Parents were of Irish ancestry without any known consanguinity. He has two generally healthy older siblings, although the brother's history is significant for obesity, a desmoid tumor, and macular degeneration and the sister has a history of obesity, macular degeneration, and a basal cell carcinoma. The remainder of the family history was negative for congenital anomalies, intellectual disability, multiple miscarriages/stillbirths, or known genetic diseases. The patient's mother died at age 65 yr from metastatic lung cancer with a positive smoking history. His father died in his 70s with a history of chronic obstructive pulmonary disease, macular degeneration, prostate and squamous cell cancers, and two abdominal aortic aneurysms in his 60s. The individual was evaluated at a clinical genetics clinic at age 55. On physical exam, he had short stature with a height of 1.6 m (5′3′′) and a weight of 62.1 kg (136.7 lb). Dysmorphic features included macrocephaly (head circumference >99 percentile), narrow palpebral fissures, prominent forehead, large thickened ears, wide mouth, and a hypoplastic maxilla (Fig. 2). Soft, loose skin was present on the face, neck, back, dorsal, and palmar/plantar sides of hands and feet. Significant kyphoscoliosis, reduced elbow extension, small hands and feet, and high foot arches were also noted. He had a protruding chest and widely spaced nipples. Because of the intellectual disability and dysmorphic features, a chromosomal microarray was performed. Fragile X testing was also sent secondary to the history of a male with large ears, attention-deficit/hyperactivity disorder (ADHD), seizures, and intellectual disability. A Noonan spectrum and RASopathy gene panel were also sent with the phenotypic overlap with Costello syndrome. Those tests were nondiagnostic, and so clinical testing was advanced to WES with mitochondrial DNA analysis.
Figure 2.

Front and side images of patient's head. From the front (A), the macrocephaly, prominent forehead, loose skin, and wide mouth are evident. Profile view (B) shows the large, thickened ears and hypoplastic maxilla. Hand photo (C) demonstrates soft, loose skin over the palmar side.

Front and side images of patient's head. From the front (A), the macrocephaly, prominent forehead, loose skin, and wide mouth are evident. Profile view (B) shows the large, thickened ears and hypoplastic maxilla. Hand photo (C) demonstrates soft, loose skin over the palmar side.

Whole-Exome Sequencing

Determination of the DNA sequence of the coding regions of the genomes of the individual and his unaffected brother and sister by WES revealed that he harbored a heterozygous variant in the AHDC1 gene that would be predicted to lead to protein truncation, consistent with the diagnosis of XGS. The individual's parents were deceased and unavailable to confirm de novo status. However, neither unaffected sibling harbored the variant. The observed variant [NM_001029882.2:c.979C>T (p.Gln327*)] is predicted to cause the disorder either through the presence of the truncated form of the protein (i.e., a dominant negative effect) or else through haploinsufficiency, via the absence of sufficient normal protein. The AHDC1 c.979C>T (p.Gln327*) variant was not observed in the Genome Aggregation Database (gnomAD) or ExAC databases (Lek et al. 2016) and was predicted to be damaging, by in silico algorithms (Table 2). Per ACMG criteria (Richards et al. 2015), this AHDC1 variant was classified as “likely pathogenic.”
Table 2.

Allele frequency, predicted pathogenicity of variants detected on exome, and mitochondrial sequencing

GeneGenomic location (GRCh37)Nucleotide changeAmino acid changeZygosityCADD PhredMax allele freqaACMG interpretation
AHDC1Chr 1:27877648G > ANM_001029882.2:c.979C > Tp.Gln327*Heterozygous370Likely pathogenic
NSUN5Chr 7:72721622G > ANM_018044.4:c.349C > Tp.Arg117TrpHeterozygous25.20.0022VUS
NSUN5Chr 7:72721419C > GNM_018044.4:c.472G > Cp.Gly158ArgHeterozygous26.60.00047VUS
MT-THNC_012920.1:m.12191C > THomoplasmicVUS

(VUS) Variant of uncertain significance; (*) gnomAD frequency.

Allele frequency, predicted pathogenicity of variants detected on exome, and mitochondrial sequencing (VUS) Variant of uncertain significance; (*) gnomAD frequency. Whole-exome sequencing also revealed two variants of uncertain significance (VUSs) in the NSUN5 gene [NM_018044.4:c.349C>T (p.Arg117Trp) and c.472G>C (p.Gly158Arg)]. Segregation analysis confirmed these variants to be in trans as each unaffected sibling carried one of the alleles. The contribution of the NSUN5 variants to the individual's phenotype is unknown at this time, because this gene has no current disease association. Mitochondrial genome sequencing identified a homoplasmic VUS in the MT-TH gene (NC_012920.1:m.12191C>T) in the individual. Targeted testing in an unaffected maternal aunt showed the same homoplasmic variant, suggesting that it was most likely noncontributory to the individual's phenotype.

DISCUSSION

At age 55 yr at the time of diagnosis, this individual is the oldest known case of XGS, an autosomal dominant disorder caused by de novo truncating variants in the AHDC1 gene (Xia et al. 2014). XGS has traditionally been diagnosed in the pediatric setting, with the majority of cases less than 10 yr of age at diagnosis and the oldest being 29 yr old (García-Acero and Acosta 2017; Jiang et al. 2018; Ritter et al. 2018). Affected individuals commonly have hypotonia, intellectual disability, dysmorphic features, and brain anomalies, but the phenotype can be variable. The patient described here shares many of those features, including the dysmorphisms, intellectual disability, and brain atrophy. There are notable differences, however, that may be important in the management of aging patients with XGS and may provide insight into the natural history of the disorder. The common, rare, and unique features in this case compared to those previously described are summarized in Table 1. One notable difference in this case is the absence of hypotonia, a finding in 90% of previously described cases (Jiang et al. 2018). This individual's tone was normal, and he was actually quite strong on exam. Nevertheless, he has significant coordination difficulties with an ataxic gate and poor balance. Sleep apnea is another common finding with XGS that was not seen here despite the presence of general sleep disruption. Craniosynostosis has been reported in 3/19 (15.8%) XGS cases recently described (Ritter et al. 2018) but was not noted on this individual's exam or imaging. Interestingly, this individual had significant macrocephaly (head circumference >99 percentile), a finding that can occasionally be seen with Muenke syndrome, an FGFR3-related craniosynostosis condition (Kruszka et al. 1993). At this time, however, it is unclear what role, if any, AHDC1 mutations play in this condition of premature cranial suture closure (Miller et al. 2017). The patient's unique history of a benign thyroid mass, nerve sheath tumor (benign Schwannoma), and melanoma is notable and suggests a possible increased risk for malignancy. The function of AHDC1 is not well understood but it shares a domain with REV3L, a gene implicated in DNA translesion repair (Fig. 3; Gan et al. 2008). Inherited defects in DNA repair mechanisms are known to carry a higher cancer risk, for example skin cancer in xeroderma pigmentosa (Gan et al. 2008). Until we better understand the complete function of AHDC1, it is important for patients with XGS to receive age-appropriate cancer screening (colonoscopy, mammogram, etc.) and to have a low threshold for specialist referral if indicated. Similarly, as individuals with XGS progress into adulthood, they should receive proper screening and management of conditions like hypertension, as was done in this case.
Figure 3.

Graphical depiction of the known XGS-associated AHDC1 variants. Amino acid positions are on the x-axis with purple and yellow circles representing frameshift and nonsense mutations, respectively. This individual's p.Gln327* mutation is indicated by the red circle. Rectangles represent different protein domains, including AT-hook domains in pink, REV3L homology domains in green, KIAA2022 homology domains in orange, and both REV3L and KIAA2022 homology domains in blue.

Graphical depiction of the known XGS-associated AHDC1 variants. Amino acid positions are on the x-axis with purple and yellow circles representing frameshift and nonsense mutations, respectively. This individual's p.Gln327* mutation is indicated by the red circle. Rectangles represent different protein domains, including AT-hook domains in pink, REV3L homology domains in green, KIAA2022 homology domains in orange, and both REV3L and KIAA2022 homology domains in blue. One striking finding on physical exam was the individual's significant kyphoscoliosis, measuring 56° in the thoracic spine (>40° is considered severe) (Fig. 1). We recently reported scoliosis in 20% of surveyed individuals with XGS, which is a significant increase compared to a general prevalence of 5% (Jiang et al. 2018). Scoliosis occurs in connective tissue disorders, like Marfan syndrome, because of bone overgrowth and ligamentous laxity (Dietz 1993). It is also common in neuromuscular conditions, including Duchenne muscular dystrophy, Friedreich ataxia, and cerebral palsy. In these neurologic conditions, the hypothesized etiology is disorganized control of trunk muscles leading to progressive spinal imbalance and eventually to scoliosis (Vialle et al. 2013). It is likely that scoliosis in XGS is due to a similar process as a result of neurologic deficits. However, a connective tissue component cannot be excluded given that this individual also had soft, loose skin. Furthermore, a recent cohort study described connective tissue abnormalities, including the skin, in 9/19 (47%) cases (Ritter et al. 2018). Regardless of the etiology, early recognition of scoliosis in XGS permits interventions to prevent complications like life-threatening cardio-respiratory compromise. Another notable finding in this adult with XGS is his neuropsychiatric history. Behavioral issues were first observed in some XGS patients (Yang et al. 2015), and a more recent description of additional individuals noted instances of problems with impulse control, self-injurious and aggressive behavior, inappropriate social responses, and marked problems with sleep (Jiang et al. 2018). This adult had some of these behaviors that have required care of medical professionals and pharmacologic intervention. It should be noted that these features are variable in XGS patients and many are not aggressive in any way. As in all neurodevelopmental conditions, such behaviors can have profound negative impact on patient and family quality of life, jeopardizing educational opportunities or leading to residential placement, for example (McGuire et al. 2016). Thus, it is crucial to refer patients with XGS early to the appropriate specialists if they exhibit behavioral or mental health issues. The mechanism of pathogenesis for AHDC1 mutations remains unresolved. All XGS-associated mutations described to date are presumed de novo truncating variants, possibly acting through a dominant negative mechanism (Xia et al. 2014). One recently published case (Park et al. 2017) and others in the DECIPHER database (Firth et al. 2009) with developmental delay and deletions of AHDC1 and other genes suggest haploinsufficiency should also be considered as a disease mechanism. It has also been suggested that patients with early mutations in AHDC1 may have milder phenotypes and slightly higher measures of cognitive ability than those with more distal mutations (Jiang et al. 2018). However, there is significant variability, even among individuals with the same mutation, making it difficult to draw any conclusions. The frameshift mutation described here is located very early in the gene, toward the amino terminus of the encoded protein (p.Gln327*), which could suggest a milder predicted phenotype. However, though the patient is generally healthy, he has severe intellectual disability with an IQ of 30–40. In contrast, a 29-yr-old male with XGS and a very distal mutation (p.Cys1499Valfs*9) was recently described as having only moderate intellectual disability, is trilingual, and employed (Ritter et al. 2018). Thus, a larger number of cases and a better understanding of the disease mechanism is needed to elucidate any true genotype-phenotype correlations. Until recently, XGS has largely been considered a disorder of childhood. Of the >100 XGS cases described to date, the three oldest are only in their 20s (Jiang et al. 2018; Ritter et al. 2018), demonstrating that our understanding of the natural history of XGS is limited. Genetic diseases are often well described in the pediatric age range because that is when they are typically diagnosed. In a recent study describing data from 2000 WES cases performed in a clinical setting, only 12% were adult patients (Yang et al. 2014). The adult phenotype may not be well defined or may be unfamiliar to the adult physician. For example, a recent study of screening copy number variation in adults demonstrated that only one in 12 adults had been correctly diagnosed with the 22q11.2 deletion syndrome though 10 of 12 had clinical features consistent with the diagnosis (e.g., congenital heart defect, neurodevelopmental disorder) (Maxwell et al. 2017). Phenotypic expression may also be subtler in adulthood, because of mosaicism or variable expressivity. As a consequence, WES may currently be underutilized in adults with intellectual disability in whom phenotypes are less defined. Nevertheless, the diagnostic utility of WES in adults has been demonstrated, for example in one study in which a molecular diagnosis was made in 17.5% of adults undergoing WES, rising to 27.7% in those with neurodevelopmental abnormalities like this case (Posey et al. 2016). It may also suggest that AHDC1 might be implicated in some fraction of institutionalized adults that have never undergone a genetic evaluation. In conclusion, this case represents the oldest individual diagnosed with XGS to date. Overall, he remains healthy well into his 50s, suggesting that life span may not be dramatically altered in XGS. With continued support and interventions, such individuals may continue to thrive into adulthood. This report suggests that XGS should be considered in the differential diagnosis of adults with unexplained intellectual disability and dysmorphic features. Last, it demonstrates the need to generally consider classically defined pediatric conditions in adults.

METHODS

Using genomic DNA from the submitted specimens, the exonic regions and flanking splice junctions of the genome were captured and sequenced at GeneDx on an Illumina system with 150-bp paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19 and then analyzed for sequence variants. Potentially pathogenic variants were confirmed with Sanger sequencing. Mean depth of coverage was 123×, and 98.7% of the targeted region was sequenced to a coverage of at least 10× (Table 3).
Table 3.

Whole-exome sequencing metrics

Mean depth of coverage123×
Percentage of exome with at least 10× coverage98.70%
Percentage of AHDC1 coding region with at least 10× coverage100%
Whole-exome sequencing metrics

ADDITIONAL INFORMATION

Data Deposition and Access

The confirmed genetic variant was deposited to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) under accession number SCV000618821. Whole-exome sequencing data are not publicly available because consent could not be obtained.

Ethics Statement

Written consent for the case report and pictures was obtained from the individual's guardian. The study was approved by the Institutional Review Board of Baylor College of Medicine.

Acknowledgments

We thank the subject of this case report and his family for their generous contributions.

Author Contributions

All authors were involved in the study design, manuscript preparation, and data analysis, as well as reviewing, of the final manuscript.

Funding

This work was supported by the Baylor-Hopkins Center for Mendelian Genomics (HG006542) and by a private donation. R.A.G. was also supported as a visiting scholar of the Texas Institute for Advanced Studies.

Competing Interest Statement

Jane Juusola and Kirsty McWalter are employees of GeneDx.
  16 in total

1.  Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care.

Authors:  Kelly McGuire; Lawrence K Fung; Louis Hagopian; Roma A Vasa; Rajneesh Mahajan; Pilar Bernal; Anna E Silberman; Audrey Wolfe; Daniel L Coury; Antonio Y Hardan; Jeremy Veenstra-VanderWeele; Agnes H Whitaker
Journal:  Pediatrics       Date:  2016-02-01       Impact factor: 7.124

2.  Variable Clinical Manifestations of Xia-Gibbs syndrome: Findings of Consecutively Identified Cases at a Single Children's Hospital.

Authors:  Alyssa L Ritter; Carey McDougall; Cara Skraban; Livija Medne; Emma C Bedoukian; Stephanie B Asher; Jorune Balciuniene; Colleen D Campbell; Samuel W Baker; Elizabeth H Denenberg; Sarah Mazzola; Sarah K Fiordaliso; Ian D Krantz; Paige Kaplan; Lynne Ierardi-Curto; Avni B Santani; Elaine H Zackai; Kosuke Izumi
Journal:  Am J Med Genet A       Date:  2018-08-27       Impact factor: 2.802

3.  Molecular findings among patients referred for clinical whole-exome sequencing.

Authors:  Yaping Yang; Donna M Muzny; Fan Xia; Zhiyv Niu; Richard Person; Yan Ding; Patricia Ward; Alicia Braxton; Min Wang; Christian Buhay; Narayanan Veeraraghavan; Alicia Hawes; Theodore Chiang; Magalie Leduc; Joke Beuten; Jing Zhang; Weimin He; Jennifer Scull; Alecia Willis; Megan Landsverk; William J Craigen; Mir Reza Bekheirnia; Asbjorg Stray-Pedersen; Pengfei Liu; Shu Wen; Wendy Alcaraz; Hong Cui; Magdalena Walkiewicz; Jeffrey Reid; Matthew Bainbridge; Ankita Patel; Eric Boerwinkle; Arthur L Beaudet; James R Lupski; Sharon E Plon; Richard A Gibbs; Christine M Eng
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

Review 4.  DNA polymerase zeta (pol zeta) in higher eukaryotes.

Authors:  Gregory N Gan; John P Wittschieben; Birgitte Ø Wittschieben; Richard D Wood
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

Review 5.  Neuromuscular scoliosis.

Authors:  R Vialle; C Thévenin-Lemoine; P Mary
Journal:  Orthop Traumatol Surg Res       Date:  2013-01-19       Impact factor: 2.256

6.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.

Authors:  Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

7.  The phenotypic spectrum of Xia-Gibbs syndrome.

Authors:  Yunyun Jiang; Michael F Wangler; Amy L McGuire; James R Lupski; Jennifer E Posey; Michael M Khayat; David R Murdock; Luis Sanchez-Pulido; Chris P Ponting; Fan Xia; Jill V Hunter; Qingchang Meng; Mullai Murugan; Richard A Gibbs
Journal:  Am J Med Genet A       Date:  2018-04-25       Impact factor: 2.802

8.  Diagnostic value of exome and whole genome sequencing in craniosynostosis.

Authors:  Kerry A Miller; Stephen R F Twigg; Simon J McGowan; Julie M Phipps; Aimée L Fenwick; David Johnson; Steven A Wall; Peter Noons; Katie E M Rees; Elizabeth A Tidey; Judith Craft; John Taylor; Jenny C Taylor; Jacqueline A C Goos; Sigrid M A Swagemakers; Irene M J Mathijssen; Peter J van der Spek; Helen Lord; Tracy Lester; Noina Abid; Deirdre Cilliers; Jane A Hurst; Jenny E V Morton; Elizabeth Sweeney; Astrid Weber; Louise C Wilson; Andrew O M Wilkie
Journal:  J Med Genet       Date:  2016-11-24       Impact factor: 6.318

9.  Analysis of protein-coding genetic variation in 60,706 humans.

Authors:  Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2016-08-18       Impact factor: 49.962

10.  De novo truncating variants in the AHDC1 gene encoding the AT-hook DNA-binding motif-containing protein 1 are associated with intellectual disability and developmental delay.

Authors:  Hui Yang; Ganka Douglas; Kristin G Monaghan; Kyle Retterer; Megan T Cho; Luis F Escobar; Megan E Tucker; Joan Stoler; Lance H Rodan; Diane Stein; Warren Marks; Gregory M Enns; Julia Platt; Rachel Cox; Patricia G Wheeler; Carrie Crain; Amy Calhoun; Rebecca Tryon; Gabriele Richard; Patrik Vitazka; Wendy K Chung
Journal:  Cold Spring Harb Mol Case Stud       Date:  2015-10
View more
  8 in total

1.  Novel AHDC1 Gene Mutation in a Brazilian Individual: Implications of Xia-Gibbs Syndrome.

Authors:  Augusto C Cardoso-Dos-Santos; Thiago Oliveira Silva; Anderson Silveira Faccini; Thayne Woycinck Kowalski; Aida Bertoli-Avella; Jonas A Morales Saute; Lavinia Schuler-Faccini; Fabiano de Oliveira Poswar
Journal:  Mol Syndromol       Date:  2020-02-01

2.  Phenotypic and protein localization heterogeneity associated with AHDC1 pathogenic protein-truncating alleles in Xia-Gibbs syndrome.

Authors:  Michael M Khayat; He Li; Varuna Chander; Jianhong Hu; Adam W Hansen; Shoudong Li; Josh Traynelis; Hua Shen; George Weissenberger; Fabio Stossi; Hannah L Johnson; James R Lupski; Jennifer E Posey; Aniko Sabo; Qingchang Meng; David R Murdock; Michael Wangler; Richard A Gibbs
Journal:  Hum Mutat       Date:  2021-03-06       Impact factor: 4.878

3.  Utility of next-generation sequencing in genetic testing and counseling of disorders involving the musculoskeletal system-trends observed from a single genetic unit.

Authors:  Gayatri R Iyer; Roshan Kumar; Subhadra Poornima; Aruna Priya Kamireddy; Keerthi Konda Juturu; Lekhangda Bhatnagar; Srinka Arora; Vaishnavi Suresh; Prashant R Utage; Sarah Bailur; Akhilesh N Pujar; Qurratulain Hasan
Journal:  J Orthop Surg Res       Date:  2022-02-05       Impact factor: 2.359

Review 4.  Genotype-phenotype spectrum and correlations in Xia-Gibbs syndrome: Report of five novel cases and literature review.

Authors:  Ferruccio Romano; Mariateresa Falco; Gerarda Cappuccio; Nicola Brunetti-Pierri; Fortunato Lonardo; Annalaura Torella; Maria Cristina Digilio; Maria Lisa Dentici; Paolo Alfieri; Emanuele Agolini; Antonio Novelli; Livia Garavelli; Andrea Accogli; Pasquale Striano; Gioacchino Scarano; Vincenzo Nigro; Marcello Scala; Valeria Capra
Journal:  Birth Defects Res       Date:  2022-06-18       Impact factor: 2.661

5.  AT-hook DNA-binding motif-containing protein one knockdown downregulates EWS-FLI1 transcriptional activity in Ewing's sarcoma cells.

Authors:  Takao Kitagawa; Daiki Kobayashi; Byron Baron; Hajime Okita; Tatsuo Miyamoto; Rie Takai; Durga Paudel; Tohru Ohta; Yoichi Asaoka; Masayuki Tokunaga; Koji Nakagawa; Makoto Furutani-Seiki; Norie Araki; Yasuhiro Kuramitsu; Masanobu Kobayashi
Journal:  PLoS One       Date:  2022-10-04       Impact factor: 3.752

6.  Focusing on Autism Spectrum Disorder in Xia-Gibbs Syndrome: Description of a Female with High Functioning Autism and Literature Review.

Authors:  Stefania Della Vecchia; Roberta Milone; Romina Cagiano; Sara Calderoni; Elisa Santocchi; Rosa Pasquariello; Roberta Battini; Filippo Muratori
Journal:  Children (Basel)       Date:  2021-05-26

7.  Community-based recruitment and exome sequencing indicates high diagnostic yield in adults with intellectual disability.

Authors:  Aniko Sabo; David Murdock; Shannon Dugan; Qingchang Meng; Marie-Claude Gingras; Jianhong Hu; Donna Muzny; Richard Gibbs
Journal:  Mol Genet Genomic Med       Date:  2020-08-07       Impact factor: 2.183

8.  AHDC1 missense mutations in Xia-Gibbs syndrome.

Authors:  Michael M Khayat; Jianhong Hu; Yunyun Jiang; He Li; Varuna Chander; Moez Dawood; Adam W Hansen; Shoudong Li; Jennifer Friedman; Laura Cross; Emilia K Bijlsma; Claudia A L Ruivenkamp; Francis H Sansbury; Jeffrey W Innis; Jessica Omark O'Shea; Qingchang Meng; Jill A Rosenfeld; Kirsty McWalter; Michael F Wangler; James R Lupski; Jennifer E Posey; David Murdock; Richard A Gibbs
Journal:  HGG Adv       Date:  2021-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.